BRAF and medullary thyroid gland carcinoma: Although recently, point mutations in BRAF and RAS genes and also abnormal expression of non-coding miRNA have been described for sporadic MTC for therapeutic goals, more work is needed on the molecular pathogenesis of MTC and on the genetic defects and altered cellular signaling pathways involved in the tumorigenesis of human MTC.